Nuvation Bio Inc

NUVB remains in a Stage 2 advancing regime with a robust uptrend confirmed by rising EMAs and continuation patterns. The Devil’s Bargain cluster underscores sustained demand despite extreme overbought readings. Price is pulling back into the 9/21 EMA confluence, offering a favorable shallow pullback entry. Execution is focused on buying now at EMA support, while monitoring for a decisive breakdown below the EMAs as invalidation.

• ↑Ibtrozi net sales grew 18% Q/Q to $18.5M with ~200 new patient starts.
• ↑89% overall response rate and 50-month median duration highlight efficacy.
• ↓Operating expenses reached $73.5M last quarter, straining financials.